Pharmaceutical Technology's In the Lab eNewsletter
The new NAB Nanosep device provides increased binding capacity.
Pall’s newly introduced nucleic acid binding (NAB) Nanosep centrifugal device provides increased binding capacity through an innovative dual-layer, silica-based quartz glass fiber membrane. It can be used for applications that require highly efficient nucleic acid isolation.
Researchers using this multipurpose NAB Nanosep device can purify plasmid DNA, genomic DNA, or total RNA from a variety of starting materials. The centrifugal device can recover from 10,000 to 50 base pairs, allowing users to analyze the widest range of nucleic acid fragments in a single spin device, Pall announced in a March 11, 2020 press release.
The device offers flexibility and rapid processing without sacrificing yield or quality of the nucleic acids. Its double-layer membrane can isolate nucleic acids with yields high enough to allow multiple downstream applications, which can save time and cost by eliminating the need to process additional samples. The device has ultrasonically welded seals to prevent bypass contamination or seal failure and fits standard centrifuge rotors that accept 1.5-mL tubes.
The NAB Nanosep device is ideal for applications in the following workflows:
Source: Pall
Drug Solutions Podcast: Applying Appropriate Analytics to Drug Development
March 26th 2024In this episode of the Drug Solutions Podcast, Jan Bekker, Vice President of Business Development, Commercial and Technical Operations at BioCina, discusses the latest analytical tools and their applications in the drug development market.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.